Cancer Genetics, Inc. CEO Panna Sharma to Present at the 4th Annual Life Science Chief Executive Officer Forum

RUTHERFORD, N.J., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, today announced its CEO Panna Sharma will present at the 4th Annual Life Science Chief Executive Officer Forum on January 30, 2014 at 4:15 p.m. ET. The Forum will be a place for CEOs and executive to discuss changes in the healthcare system, both in the US as well as abroad and how they are altering the traditional business model of the life science corporation, and as a result, how leading corporations both small & large are considering new business strategies and methodologies that will ultimately ensure the success of their corporations.

Mr. Sharma's presentation, "Achieving Strategic & Financial Objectives through an Initial Public Offering," is part of the forum's efforts to provide executives throughout the pharmaceutical & medical device industries with the strategies they need to continue the growth of their organizations.

The Life Science CEO Forum will include leaders from a range of life science companies, including, Life Technologies, Takeda, Sanofi, Aetna, and Johnson and Johnson. Additional information about the event, which takes place January 29-31 in Raleigh-Durham, NC, can be accessed via: www.q1productions.com/conferencepost/ceoforum/.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 jon@redchip.comSource:Cancer Genetics